AGIOS PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
AGIOS PHARMACEUTICALS, INC. (AGIO) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $224.00 million as of 2020-03-31, per its 10-Q filed 2020-04-30.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2020-04-30
- 2020-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $224.00M.
- 2019-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $345.70M.
- 2019-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $159.80M.
- 2019-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $175.50M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2020-03-31 | $224.00M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $345.70M 10-Q · filed 2020-04-30 |
| 2019-09-30 | $159.80M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $175.50M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $362.60M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $639.30M 10-K · filed 2020-02-19 |
| 2018-09-30 | $659.80M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $616.50M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $572.70M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $439.40M 10-K · filed 2019-02-14 |
| 2017-09-30 | $435.50M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $482.70M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $241.80M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $335.40M 10-K · filed 2018-02-14 |
| 2015-12-31 | $207.40M 10-K · filed 2017-02-16 |
| 2014-12-31 | $236.90M 10-K · filed 2016-02-26 |
| 2014-09-30 | $21.50M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $57.40M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $17.00M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $31.70M 10-K · filed 2015-02-24 |
| 2013-09-30 | $6.20M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $8.00M 10-Q · filed 2013-09-05 |
| 2012-12-31 | $13.70M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |